Core Viewpoint - The company, Qianxin Biotech-B (02509), has seen its stock price increase by over 3%, currently trading at HKD 20.9 with a transaction volume of HKD 3.0619 million [1] Group 1: Financial Milestones - The company announced it received a milestone payment of USD 5 million from its partner Caldera Therapeutics, Inc, triggered by the approval of QX030N/CLD-423 for Phase I clinical trials by the Human Research Ethics Committee [1] - This payment signifies a key financial achievement for the company as it progresses in its clinical development [1] Group 2: Clinical Development - The dual antibody QX030N/CLD-423 has received approval from the HREC in Australia and is set to initiate clinical trials in early 2026 [1] - This approval marks a significant step for the company's dual antibody matrix strategy, officially entering the clinical phase overseas [1] - The company and Caldera are expected to accelerate project development to achieve further clinical progress [1]
荃信生物-B再涨超3% 双抗矩阵布局在海外正式迈入临床阶段